Oropharyngeal Cancer
Conditions
Brief summary
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Detailed description
This study is being conducted in order to find out if this approach is as good as the usual approach in controlling the cancer and has fewer side effects and better quality of life. The usual approach for patients who are not in a study is treatment which includes radiotherapy to the tumour and to both sides of the neck to decrease the risk of spread or recurrence of the cancer
Interventions
Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
RADIATIONIpsilateral and Contralateral Neck
Radiotherapy
Sponsors
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
NRG Oncology
SWOG Cancer Research Network
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with pathologically proven diagnosis of lateralized OPC (tonsil, tongue base, soft palate, or pharyngeal wall) not involving or crossing midline. * HPV positive or negative (by p16 immunohistochemistry). * Clinical stage T1-3 M0 (UICC/AJCC TNM 8th Edition). Nodal involvement may include no nodes or single or multiple ipsilateral lymph nodes (largest ≤6cm in maximum diameter) * Radiological investigations within 8 weeks of registration: * CT or MRI of the neck (with head imaging as indicated); * PET-CT scan * Chest CT scan * Planned definitive RT or CRT with bilateral neck RT (patients planned for unilateral neck RT are excluded). * Intent to deliver concurrent chemotherapy or not must be known at the time of randomization. As this is a pragmatic trial, even patients who are not candidates for systemic therapy will be eligible for participation. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. * Willing to complete the quality of life and/or health utility questionnaire, if sufficiently fluent in available language(s). * Informed consent prior to registration * Accessible for treatment and follow-up. * Commencement of definitive RT within 28 days (+ 14 days) of randomization. * Injection procedure for lymphatic mapping may be performed in the nuclear medicine, ambulatory clinic, or operating room setting * Women/men of childbearing potential must have agreed to use a highly effective contraceptive method * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Patient must consent to provision of, and investigator(s) must confirm location and commitment to obtain a representation of formalin fixed paraffin block of non-cytology tumour tissue in order that the specific correlative marker assays
Exclusion criteria
* T1-T2 cancers isolated to the tonsil fossa (i.e. without any soft palate, tongue base, posterior pharyngeal wall or posterior tonsil pillar involvement) with no involved lymph nodes or with a single ipsilateral node \< 3 cm without extranodal extension. * Tonsil or tongue base primary cancer who have previously undergone diagnostic palatine or lingual tonsillectomy with either complete excision or with no clinically apparent residual disease * Previous head and neck cancer or multiple synchronous primary head and neck cancers * Previous induction or neo-adjuvant chemotherapy. * Previous radiation therapy to the head and neck or comprehensive neck dissection of at least 3 levels on either side (due to potential for disrupted lymphatic channels and drainage pathways). Patients who have had excisional biopsies of involved lymph nodes are eligible * Radiotracer allergy * Severe, active co-morbidity including any of the following: * Chronic Obstructive Pulmonary Disease or other pulmonary illness requiring hospitalization within 30 days of registration * Unstable angina and/or congestive heart failure requiring hospitalization within the 30 days of registration * Acute myocardial infarction within 30 days of study registration * Diseases precluding RT (e.g. scleroderma)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free Survival | 8 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life using M.D. Anderson Dysphagia Inventory (MDADI) | 8 years | Possible range of scores between 0 and 100 (higher scores indicating better swallowing and lower score indicating poor swallowing). |
| Xerostomia-related Quality of Life using Xerostomia Questionnaire (XQ) | 8 years | Clinically meaningful worsening of xerostomia (10 units on XQ) from baseline to 12 months post RT |
| Isolated contralateral neck failure (iCNF) | 8 years | — |
| Overall Survival (OS) | 8 years | — |
| Logo-regional Failure (LRF) | 8 years | — |
| Distant Metastases (DM) | 8 years | — |
| Incidence and Severity of Radiation-related Toxicities | 8 years | — |
| Patient-Reported Toxicities using PRO CTCAE | 8 years | — |
| Gastrostomy Tube Usage | 8 years | — |
| Resource Utilization | 8 years | — |
| Lost Productivity | 8 years | Healthcare system and societal resources will be quantified over the course of the trial to generate utilization information by patient in each study arm. We will generate an average cost per study subject by treatment arm for an overall mean cost per study arm |
| Financial Toxicity [Financial Index of Toxicity (FIT)] | 8 years | — |
| Health Utilities using EQ-5D | 8 years | — |
Countries
Canada, United States
Contacts
CONTACTWendy Parulekar
STUDY_CHAIRJohn R de Almeida
University Health Network, Princess Margaret Hospital, Toronto ON Canada
STUDY_CHAIRAli Hosni
University Health Network, Princess Margaret Hospital, Toronto ON Canada
Outcome results
None listed